TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07087197: A Multicenter, Open-label Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of SKB107 in Subjects With Advanced Solid Tumors With Bone Metastases

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07087197 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07087197 Rescue Dossier →